Bygliv-Met 50/1000mg

Anti-Diabetic

Combinations of oral blood glucose lowering drugs, Bygliv-Met combines two different oral anti-hyperglycemic agents with complimentary mechanisms of action to improve glycemic control in patients with type 2 Diabetes: Vidagliptin, a member of the islet enhancer class, and metformin hydrochloride, a member of the biguanide class. Vidagliptin, a member of the islet enhancer class, is a potent and selective dipeptidyl peptidase-4 (DDP-4) inhibitor. Metformin acts primarily by decreasing endogenous hepatic glucose production.

Description

Combinations of oral blood glucose lowering drugs, Bygliv-Met combines two different oral anti-hyperglycemic agents with complimentary mechanisms of action to improve glycemic control in patients with type 2 Diabetes: Vidagliptin, a member of the islet enhancer class, and metformin hydrochloride, a member of the biguanide class. Vidagliptin, a member of the islet enhancer class, is a potent and selective dipeptidyl peptidase-4 (DDP-4) inhibitor. Metformin acts primarily by decreasing endogenous hepatic glucose production.